Description
CJC-1295 (Growth Hormone Releasing Hormone Analog)
CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH) that has been modified to extend its half-life and duration of action. This research peptide stimulates the pituitary gland to release growth hormone (GH) in a pulsatile manner, mimicking the body’s natural GH secretion patterns.
Chemical Makeup
CJC-1295 is a 30-amino acid peptide hormone that has been modified with Drug Affinity Complex (DAC) technology. This modification allows the peptide to bind to albumin in the bloodstream, significantly extending its half-life from minutes to approximately 6-8 days. The modified structure prevents rapid degradation while maintaining biological activity.
Research and Clinical Studies
CJC-1295 and Growth Hormone Release
Clinical studies have demonstrated that CJC-1295 significantly increases growth hormone and IGF-1 levels. Research shows that a single injection of CJC-1295 can elevate GH levels by 2-10 fold for up to 6 days. A landmark study published in JAMA showed that CJC-1295 administration resulted in mean increases in serum GH concentrations of 2-3 fold and IGF-1 concentrations increased by approximately 1.5-3 fold in a sustained fashion.
The peptide maintains the pulsatile nature of GH release, which is important for optimal physiological effects. Unlike continuous GH administration, CJC-1295 preserves the natural peaks and troughs of GH secretion, potentially leading to better outcomes with fewer side effects.
CJC-1295 and Muscle Growth
Research indicates that CJC-1295 may support increased lean body mass and muscle protein synthesis. Studies have shown average increases in lean body mass of 2-4 pounds over 8-12 weeks without significant changes in body fat. The peptide appears to enhance muscle recovery and may increase strength output. One study demonstrated a 15% improvement in muscle recovery times and a 12% increase in strength metrics over a 90-day period.
CJC-1295 and Body Composition
Research suggests that CJC-1295 may improve overall body composition by increasing lean mass while reducing fat mass. Studies have observed modest reductions in abdominal fat (approximately 1-3% decrease) along with improvements in muscle mass. The peptide may also improve bone density, with some research showing increases of 2-5% in bone mineral density over extended use periods.
CJC-1295 and Recovery
Studies indicate that elevated GH levels from CJC-1295 may enhance recovery from training and injury. Research shows improvements in sleep quality, with subjects reporting deeper sleep and better recovery. The peptide may also support connective tissue repair and joint health through increased collagen synthesis.
CJC-1295 is available for research and laboratory purposes only. Please review our Terms and Conditions before placing an order.
References:
1. Teichman SL, et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805.
2. Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab. 2006;91(12):4792-4797.









Reviews
There are no reviews yet.